article thumbnail

Managing Adverse Events Associated with HE Therapies

Pharmacy Times

Riello, PharmD, BCPS, discusses the adverse events associated with hepatic encephalopathy (HE) treatments and the importance of encouraging patients to continue first-line medications despite adverse reactions to prevent HE recurrence.

article thumbnail

IPC alert advises patients to monito possibility of mefenamic acid’s adverse effects: Meftal makers

Express Pharma

DRESS syndrome, mentioned in the IPC alert, is a very rare event that is previously documented in medical literature, both in India and globally. The post IPC alert advises patients to monito possibility of mefenamic acid’s adverse effects: Meftal makers appeared first on Express Pharma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New CAR-T therapies in South Korea to face stringent regulatory oversight: GlobalData

Express Pharma

This will ensure a comprehensive database of adverse events including malignancies, if any in the local population, thereby ensuring patient safety in the country. However, regulatory focus on malignancy data might extend clinical trial timelines and increase costs for pipeline therapies, says GlobalData.

article thumbnail

Adverse Drug Reactions

RX Note

Adverse Drug Reactions The World Health Organization (WHO) defines an adverse drug reaction (ADR) as 'a drug-related event that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function'.

article thumbnail

Anaemia in Chronic Kidney Disease

RX Note

Studies suggest that treatment with ESAs to high Hgb concentrations (greater than 13 g/dL) increases cardiovascular events. The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) , for example, failed to show a benefit in outcomes, but treatment with ESAs was associated with increased stroke.

article thumbnail

AZ, J&J COVID-19 vaccine trials okay to restart in US

pharmaphorum

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. There are many possible factors that could have caused the event.”.

article thumbnail

FDA approves first treatment for geographic atrophy

European Pharmaceutical Review

A milestone for retinal ophthalmology The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade.” It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision.